Litcius/Paper detail

Human placental-derived stem cell therapy ameliorates experimental necrotizing enterocolitis

Victoria G. Weis, Anna Deal, Gehad Mekkey, Cara Clouse, Michaela Gaffley, Emily E. Whitaker, Cole B. Peeler, Jared A. Weis, Marshall Z. Schwartz, Anthony Atala

2021American Journal of Physiology-Gastrointestinal and Liver Physiology26 citationsDOIOpen Access PDF

Abstract

These studies demonstrate a human placental-derived stem cell (hPSC) therapeutic strategy for necrotizing enterocolitis (NEC). In an experimental model of NEC, hPSC administration improved macroscopic intestinal health, ameliorated epithelial morphology, and supported the intestinal stem cell niche. Our data suggest that hPSC are a potential therapeutic approach to attenuate established intestinal NEC damage. Further, we show hPSC are a novel research tool that can be utilized to elucidate critical neonatal repair mechanisms to overcome NEC.

Topics & Concepts

Necrotizing enterocolitisPaneth cellCryptStem cellLGR5IleumStem-cell therapyProgenitor cellApoptosisMedicineEnterocolitisIntestinal DisorderPathologyBiologyInternal medicineSmall intestineCell biologyCancer stem cellDiseaseBiochemistryInfant Nutrition and HealthNeonatal Respiratory Health ResearchCongenital Anomalies and Fetal Surgery
Human placental-derived stem cell therapy ameliorates experimental necrotizing enterocolitis | Litcius